Search Database ICD-O-3 Code Lists

Name

Primary cutaneous T-cell lymphoma

ICD-O-2 Morphology

Effective 1992 - 2000

ICD-O-3 Morphology

9709/3: Cutaneous T-cell lymphoma, NOS
Effective 2001 and later

Reportable

for cases diagnosed 1992 and later

Primary Site(s)

C440-C449, C510-C512, C518-C519, C600-C602, C608-C609, C632
Cutaneous (skin) lymphoma which presents with generalized skin lesions. See Module 7.

Coding Manual: Hematopoietic Coding Manual (PDF)

Abstractor Notes

This code should rarely be used for cutaneous T-cell lymphoma, NOS. Diagnosis of a more specific T-cell neoplasm should be possible. Use this NOS term only for HISTORIC CASES, DCO cases, or path-only cases when additional information is not available.

Note: When there is a pre-2010 tumor coded to 9709/3 there should be careful follow-back to determine whether this new diagnosis is a new primary or a more specific diagnosis of T-cell cutaneous lymphoma.

Patients with a single lesion have an excellent prognosis and are treated with surgical excision or radiotherapy.

Diagnostic Confirmation

This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.

Grade

Not Applicable

Module Rule

None

Alternate Names

Cutaneous lymphoma, NOS [OBS]
Cutaneous T-cell lymphoma, NOS
P-CTCL
Primary cutaneous acral CD8+ T-cell lymphoma
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma

Definition

Primary cutaneous CD8+ T-cell lymphoma is a rare cutaneous tumor characterized by skin infiltration of clonal atypical medium-sized cytotoxic lymphocytes,. The tumor is clinically characterized by preferential involvement of acral sites (in particular the ear).

Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma is a cutaneous T-cell lymphoma characterized by proliferation of epidermotropic CD8+ cytotoxic T cells and aggressive clinical behavior. Differentiation from other types of cutaneous T-cell lymphomas with a CD8+ cytotoxic T-cell phenotype is based on the clinical presentation, clinical behavior, and certain histological features, such as marked epidermotropism with epidermal necrosis.

Definitive Diagnostic Methods

Genetic testing
Histologic confirmation
Immunophenotyping

Genetics Data

EBV negative
TR genes are clonally rearranged

Immunophenotyping

BCL6- (no expression/negative)
Beta F1+ (expression/positive)
CD2+ (expression/positive)
CD3+ (expression/positive)
CD4- (no expression/negative)
CD5+ (expression/positive)
CD7+ (expression/positive)
CD8+ (expression/positive)
CD10- (no expression/negative)
CD30- (no expression/negative)
CD56- (no expression/negative)
CXCL13- (no expression/negative)
CD57 - (no expression/negative)
Granzyme B+ (expression/positive)
PDI- (no expression/negative)
Perforin+ (expression/positive)
TdT- (no expression/negative)
T1A1+ (expression/positive)

Treatments

Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Hormone therapy
Immunotherapy
Other therapy
Radiation therapy
Surgery

Transformations to

Transformations from

None

Same Primaries

Corresponding ICD-9 Codes

202.8 Other lymphoma

Corresponding ICD-10 Codes

C84.5 Other and unspecified T-cell lymphomas

Corresponding ICD-10-CM Codes (U.S. only)

C84.A Cutaneous T-cell lymphoma, unspecified (effective October 01, 2015)

Signs and Symptoms

Drenching night sweats
Fatigue
Fever (for no known reason)
Pain in the chest, abdomen, or bones (for no known reason)
Ulcerated/disseminated eruptive papules, nodules and tumors
Weight loss (for no known reason)

Diagnostic Exams

Blood chemistry studies
CT (CAT) scan
Flow cytometry
Immunohistochemistry
Immunophenotyping
PET (positron emission tomography) scan
Skin biopsy

Progression and Transformation

None

Epidemiology and Mortality

Age: mostly occurs in adults
Incidence: <1% of cutaneous T-cell lymphomas
Sex: no male or female predominance
Survival: 32 months median survival

Sources

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature T- and NK-cell neoplasms
Pages: 399-401

International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577

National Cancer Institute
Section: General Information About Adult Non-Hodgkin Lymphoma (NHL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
Glossary